

Medicines for the poor

The role of WIPO


Dr. Mohga Kamal Smith
Oxfam

mksmith@Oxfam.org.uk

www.Oxfam.org.uk



Access to Medicines



The health crisis: changing pattern

Infection

**12m children die/ year from preventable & curable diseases:
8,000 die of TB/ day, 1 m die of malaria/ year**

Rising drug resistance

Chest infection-1st child killer:70% resistant to 1st line drugs

- **Diarrhoea- 2nd Second killer: 81.8% bloody diarrhoea in Tanzania are resistant to ampicillin,**
- **Gonorrhoea : in SEA 98% are penicillin resistant**

Rise in chronic disease –double burden

- **NCDs = 40% of all deaths are in DCs**
- **6 million cancer deaths/Year –1/2 in DCs**
- **10 million new cases/year->1/2 in DCs**
- **115 m out of 176 million diabetics in DCs**

Making the Medicine (1)



IPRs

▲ GPPP

▲ Philanthropy


▲ Public Funding

▲ Donations

▲ Price Reductions




Making the Medicine (2)



Role of generics


Impact of introduction of Generics on prices of ARVs and number of patient treated



WIPO Development Agenda

- Transparent policy making processes and procedures
- Working with UN (WHO) – teams of experts on health and IP – TA appropriate to countries level of development, health needs. For example how use all TRIPS flexibilities according to Doha
- Keep the mandate to promote innovation of medicines that reach those who need them
- Willingness to address development agenda. Consider: IP as one means to innovation and not an end in itself
- NO more IPRs! Find the impact of TRIPS first
- Long term: TRIPS reform: IPRs according to health & dev. needs

New WIPO ?



Oxfam